{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"polyglucosan-body-myopathy-type-2","columns":[{"gene":"","key":"population-ddbcfa8571b8d1766d14","label":"Polyglucosan body myopathy 2","mondoId":"MONDO:0014526","onsetQualifier":null,"originColumnKey":"MONDO:0014526/OMIM:616199","originalViews":[{"key":"MONDO:0014526/OMIM:616199","label":"Polyglucosan body myopathy 2","scopeLabel":"OMIM:616199","sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"recordKeys":["03ec3dbc19e3da21cc594b1bfe0e964d9c45b593fe92b724d754998ad7774600","048e32f947c28f6e0605fb309a6b28078dde64a3907d1a5915760c930018214f","07f0e0e93970bc30d88ed5f7eb54f31ebf276401122cbb0c05712f89a2f12fcc","30aec95cd4680582db8427c28209e3718f226323e85efa54e3cff0e90e6e8183","5b9629c3cb6d4bab841afe6d9b6397a4f516b539a0d6419455395dfd7f7094a4","6abe3463fcdadca69ab37de039e761c260425fba348b28e851e8f3cb06cad635","9df98cf4071f20f4ce5d59f6b03d487169bbdfdff510002b1cf247c447e804f6","a1aab1600b6a33854ed0ab4b61eda87ede67bd08fd09dbd0f0da9fac0550a1cf","c94470324f394aee13c3e126d81edda8f63e4e6f2038273e5de74de3fa16f94b","e4d21b78c1acfb331c6fc76cd5a6a9c8fa55d1487544292b8867d6c1c9730029","f0e0acd136be7f18dc117391fa4b1fa62b2dab98366d02abb7135b564fd06ee7","fa6da0daae65e552ab114cf764022b66c69eedf04a570b043a4b7d75a61d22b3"],"recordQualifiers":{},"scopeLabel":"OMIM:616199","sourceIds":["OMIM:616199"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-ddbcfa8571b8d1766d14"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0002460","HP:0003236","HP:0001288","HP:0030237","HP:0003325","HP:0100299","HP:0034766"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":10,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":12,"sourceGroups":{"published":12}},"features":[{"hpoId":"HP:0002460","label":"Distal muscle weakness","primary":true},{"hpoId":"HP:0003236","label":"Elevated circulating creatine kinase activity","primary":true},{"hpoId":"HP:0001288","label":"Gait disturbance","primary":true},{"hpoId":"HP:0030237","label":"Hand muscle weakness","primary":true},{"hpoId":"HP:0003325","label":"Limb-girdle muscle weakness","primary":true},{"hpoId":"HP:0100299","label":"Muscle fiber inclusion bodies","primary":true},{"hpoId":"HP:0034766","label":"Muscle fiber polyglucosan inclusion bodies","primary":true},{"hpoId":"HP:0010546","label":"Muscle fibrillation","primary":false},{"hpoId":"HP:0008946","label":"Pelvic girdle amyotrophy","primary":false},{"hpoId":"HP:0003749","label":"Pelvic girdle muscle weakness","primary":false},{"hpoId":"HP:0011727","label":"Peroneal muscle weakness","primary":false},{"hpoId":"HP:0003547","label":"Shoulder girdle muscle weakness","primary":false}],"ledeHtml":"A rare glycogen storage disease characterized by slowly progressive myopathy with storage of polyglucosan in muscle fibers. Age of onset ranges from childhood to late adulthood. Patients present proximal or proximodistal weakness predominantly of limb-girdle muscles. Variable features include exercise intolerance or myalgia. Serum creatine kinase is normal or mildly elevated. There is usually no overt cardiac involvement.","mondoId":"MONDO:0014526","node":{"canonicalSlug":"polyglucosan-body-myopathy-type-2","comparisons":[{"documentSha256":"3074104d5f07a0b8f420ae82ee9da8b1ff15a771b967feba7a0d59867f75bc82","key":"legacy-polyglucosan-body-myopathy-type-2","kind":"legacy","label":"polyglucosan body myopathy type 2","memberIds":["MONDO:0014526"],"mondoId":"MONDO:0014526","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/polyglucosan-body-myopathy-type-2.3074104d5f07a0b8f420ae82ee9da8b1ff15a771b967feba7a0d59867f75bc82.json"},{"documentSha256":"2dee54e918bc42ca58c602992ca95c819f1bf563e6fa88223b324e303e6b6922","key":"prepared-polyglucosan-body-myopathy","kind":"prepared","label":"polyglucosan body myopathy","memberIds":["MONDO:0000192","MONDO:0014389","MONDO:0014526"],"mondoId":"MONDO:0000192","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-2dee54e918bc42ca58c6.2dee54e918bc42ca58c602992ca95c819f1bf563e6fa88223b324e303e6b6922.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"Polyglucosan body myopathy type 2","originalSourceId":"ORPHA:456369","paragraphs":["A rare glycogen storage disease characterized by slowly progressive myopathy with storage of polyglucosan in muscle fibers. Age of onset ranges from childhood to late adulthood. Patients present proximal or proximodistal weakness predominantly of limb-girdle muscles. Variable features include exercise intolerance or myalgia. Serum creatine kinase is normal or mildly elevated. There is usually no overt cardiac involvement."],"rawAttribution":"MONDO:0014526","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-21T17:02:54Z","upstream":"ORPHA:456369","url":"https://rarediseases.info.nih.gov/diseases/17793"},"ownColumnKeys":["population-ddbcfa8571b8d1766d14"],"publication":"published","relationships":[{"kind":"parent","label":"polyglucosan body myopathy","mondoId":"MONDO:0000192","slug":null},{"kind":"parent","label":"GYG1-related disorder of glycogen metabolism","mondoId":"MONDO:0100314","slug":"gyg1-related-disorder-of-glycogen-metabolism"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending"},"records":[{"frequencyKind":"count","key":"03ec3dbc19e3da21cc594b1bfe0e964d9c45b593fe92b724d754998ad7774600","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616199","disease_name":"Polyglucosan body myopathy 2","evidence":"PCS","frequency_raw":"1/7","hpo_id":"HP:0003236","is_excluded":false,"label":"Elevated circulating creatine kinase activity","onset_id":null,"reference":"PMID:25272951","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"048e32f947c28f6e0605fb309a6b28078dde64a3907d1a5915760c930018214f","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:616199","disease_name":"Polyglucosan body myopathy 2","evidence":"PCS","frequency_raw":"7/7","hpo_id":"HP:0100299","is_excluded":false,"label":"Muscle fiber inclusion bodies","onset_id":null,"reference":"PMID:25272951","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"07f0e0e93970bc30d88ed5f7eb54f31ebf276401122cbb0c05712f89a2f12fcc","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:616199","disease_name":"Polyglucosan body myopathy 2","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0001288","is_excluded":false,"label":"Gait disturbance","onset_id":null,"reference":"PMID:25272951","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"30aec95cd4680582db8427c28209e3718f226323e85efa54e3cff0e90e6e8183","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:616199","disease_name":"Polyglucosan body myopathy 2","evidence":"PCS","frequency_raw":"1/7","hpo_id":"HP:0011727","is_excluded":false,"label":"Peroneal muscle weakness","onset_id":null,"reference":"PMID:25272951","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"5b9629c3cb6d4bab841afe6d9b6397a4f516b539a0d6419455395dfd7f7094a4","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:616199","disease_name":"Polyglucosan body myopathy 2","evidence":"PCS","frequency_raw":"4/7","hpo_id":"HP:0003547","is_excluded":false,"label":"Shoulder girdle muscle weakness","onset_id":null,"reference":"PMID:25272951","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"6abe3463fcdadca69ab37de039e761c260425fba348b28e851e8f3cb06cad635","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:616199","disease_name":"Polyglucosan body myopathy 2","evidence":"PCS","frequency_raw":"2/7","hpo_id":"HP:0008946","is_excluded":false,"label":"Pelvic girdle amyotrophy","onset_id":null,"reference":"PMID:25272951","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"9df98cf4071f20f4ce5d59f6b03d487169bbdfdff510002b1cf247c447e804f6","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:616199","disease_name":"Polyglucosan body myopathy 2","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0003325","is_excluded":false,"label":"Limb-girdle muscle weakness","onset_id":null,"reference":"PMID:25272951","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"a1aab1600b6a33854ed0ab4b61eda87ede67bd08fd09dbd0f0da9fac0550a1cf","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:616199","disease_name":"Polyglucosan body myopathy 2","evidence":"PCS","frequency_raw":"6/7","hpo_id":"HP:0003749","is_excluded":false,"label":"Pelvic girdle muscle weakness","onset_id":null,"reference":"PMID:25272951","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"c94470324f394aee13c3e126d81edda8f63e4e6f2038273e5de74de3fa16f94b","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:616199","disease_name":"Polyglucosan body myopathy 2","evidence":"PCS","frequency_raw":"1/7","hpo_id":"HP:0002460","is_excluded":false,"label":"Distal muscle weakness","onset_id":null,"reference":"PMID:25272951","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"e4d21b78c1acfb331c6fc76cd5a6a9c8fa55d1487544292b8867d6c1c9730029","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:616199","disease_name":"Polyglucosan body myopathy 2","evidence":"PCS","frequency_raw":"5/5","hpo_id":"HP:0034766","is_excluded":false,"label":"Muscle fiber polyglucosan inclusion bodies","onset_id":null,"reference":"PMID:26652229","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"f0e0acd136be7f18dc117391fa4b1fa62b2dab98366d02abb7135b564fd06ee7","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:616199","disease_name":"Polyglucosan body myopathy 2","evidence":"PCS","frequency_raw":"1/7","hpo_id":"HP:0030237","is_excluded":false,"label":"Hand muscle weakness","onset_id":null,"reference":"PMID:25272951","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"fa6da0daae65e552ab114cf764022b66c69eedf04a570b043a4b7d75a61d22b3","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:616199","disease_name":"Polyglucosan body myopathy 2","evidence":"PCS","frequency_raw":"3/7","hpo_id":"HP:0010546","is_excluded":false,"label":"Muscle fibrillation","onset_id":null,"reference":"PMID:25272951","source_release":"2026-06-23"},"sourceGroups":["published"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/17793\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0014526\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>ORPHA:456369</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>A rare glycogen storage disease characterized by slowly progressive myopathy with storage of polyglucosan in muscle fibers. Age of onset ranges from childhood to late adulthood. Patients present proximal or proximodistal weakness predominantly of limb-girdle muscles. Variable features include exercise intolerance or myalgia. Serum creatine kinase is normal or mildly elevated. There is usually no overt cardiac involvement.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/17793\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"polyglucosan-body-myopathy-type-2","sourceDocuments":[{"name":"GARD: Polyglucosan body myopathy type 2","reviewed":null,"source_release":"2026-10-21T17:02:54Z","url":"https://rarediseases.info.nih.gov/diseases/17793"},{"name":"MONDO: polyglucosan body myopathy type 2","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0014526"}],"sourceNote":"","synonyms":["GYG1 polyglucosan body myopathy","PGBM2","polyglucosan body myopathy 2","polyglucosan body myopathy caused by mutation in GYG1","polyglucosan body myopathy type 2"],"takeawayHtml":"","title":"polyglucosan body myopathy type 2"},"schemaVersion":1}
